Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Diffuse Large B-cell Lymphoma · Acute Lymphoblastic Leukemia · Large B-cell Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 218 (final count)
- Started
- Jun 26, 2019
- Main results expected
- Jun 30, 2027
- Fully finished
- Jul 24, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Dose recommendation: Incidence and nature of Dose Limiting Toxicities (Dose Escalation part only)
Measured over: 28 days
Phase 1: Safety: Incidence and severity of AEs and SAEs, including changes in laboratory values, ECG and vital signs
Measured over: 24 months
Phase 1: Tolerability: Ibrutinib dose modifications in the CLL/SLL arm
Measured over: 24 months
Phase 1: Manufacture success: Number of patients infused with planned target dose
Measured over: 24 months
Phase 2: Complete Response Rate (CRR) as assessed by local Investigator
Measured over: 24 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03960840 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC